查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922944

EchinocandinsB市场按产品类型、给药途径、剂型、剂量方案、包装、通路、应用和最终用户划分－2026-2032年全球预测

Echinocandin B Market by Product Type, Route Of Administration, Formulation, Dosage Regimen, Packaging, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年EchinocandinsB 市值为 2.6782 亿美元，预计到 2026 年将成长至 3.0595 亿美元，年复合成长率为 12.54%，到 2032 年将达到 6.1234 亿美元。

关键市场统计数据
基准年 2025 2.6782亿美元
预计年份：2026年 3.0595亿美元
预测年份 2032 6.1234亿美元
复合年增长率 (%) 12.54%

棘Echinocandins疗法概述：重点关注临床重要性、后勤挑战以及治疗连续性的策略要务

Echinocandins已成为治疗严重侵袭性真菌感染疾病的基石，它们凭藉良好的治疗指数和定向活性，与现有抗真菌药物物形成互补。这些药物在现代侵袭性念珠菌症临床通讯协定中至关重要，并且在某些食道念珠菌症和侵袭性曲菌症病例中，当治疗复杂且需要可靠的静脉治疗时，它们也是重要的治疗选择。过去十年，临床实务强调合理用药、快速诊断，以优化治疗效果并降低抗药性压力。

製剂创新、竞标趋势和不断发展的治疗途径正在全面重塑Echinocandins疗法的生产、采购和使用。

Echinocandins药物领域正经历着变革性的转变，这主要得益于製剂科学的进步、采购机制的转变以及临床指南的不断完善，这些因素共同改变了此类治疗方法的生产、采购和给药方式。近期製剂的创新，特别是复溶冻干製剂和预填充式注射器等产品，缩短了配製时间，最大限度地减少了给药错误，并促使医院和专科诊所重新思考住院和门诊病人输液给药方案。因此，药局部门越来越重视那些能够提高护理效率和减少病房占用时间的产品。

对 2025 年贸易政策调整如何加剧Echinocandins药物供应链的供应链风险、采购做法和进入优先事项进行综合评估。

美国2025年实施的关税政策为棘Echinocandins供应链和临床供应途径带来了巨大的成本和物流压力。上游方面，生产商面临活性药物成分和特殊材料的采购成本上涨，这给生产计画带来了压力，并促使多家契约製造生产商重新评估其地理位置和供应商多元化策略。这些变化对前置作业时间和库存缓衝产生了直接影响，导致医院和门诊中心的采购团队更加重视多源资格认证和安全库存通讯协定。

多维細項分析揭示了产品特性、临床应用和分销方式如何决定采购、管理和临床结果的机制。

详细的市场细分评估揭示了产品类型、适应症、终端用户环境、分销管道、给药途径、製剂形式、给药方案和包装形式等方面的显着差异，这些差异共同影响着采购和临床决策。在产品类型方面，阿尼芬净、卡芬净和Micafungin各自展现出不同的临床定位和操作特性，并且均有品牌药和非专利两种形式，这会影响合约策略和处方集目录的收录。临床医生会考虑这些治疗差异以及食道念珠菌症、侵袭性曲菌症和侵袭性念珠菌症等适应症。疾病严重程度和患者合併症情况指南具体的药物选择和给药方案。

从区域观点探讨采购系统、製造地和临床实践模式如何独特地影响Echinocandins的可近性和治疗的连续性。

区域趋势正显着影响Echinocandins的供应、使用模式和运作方式，导緻美洲、欧洲、中东和非洲以及亚太地区的优先事项各不相同。在美洲，以医院为中心的医疗模式和集中采购框架推动了大规模竞标，并促使医疗机构更加关注供应可靠性；同时，监管协调和管理计划也影响处方模式和药品目录的发展。这些特点使得医疗机构更加重视与供应商建立牢固的关係，并紧急时应对计画以应对供应中断。

透过供应保障、配方差异化和附加价值服务模式，为製造商、契约製造製造商和经销商提供竞争优势洞察。

製造商、契约製造製造商和经销商之间的竞争在塑造供应可靠性、产品差异化和商业策略方面发挥核心作用。药物研发公司和成熟供应商正投资于配方改进、供应链透明度和竞标应对力，以维持与医院集团和采购联盟的长期合作关係。同时，学名药参与企业和契约製造组织正在拓展认证和生产能力，以便参与多个竞标框架，从而增加大规模买家的采购选择。

为加强Echinocandins疗法的采购弹性、临床协作和供应链韧性，提出实际有效的建议

为了因应不断变化的Echinocandins市场环境，产业领导者应采取多管齐下的策略，全面保障临床治疗的连续性、采购的弹性和供应链的韧性。首先，应优先考虑供应商多元化和双重采购安排，以降低单一故障点的风险，并协商合约保障条款，包括采购量柔软性和违约处罚。其次，应投资于製剂和工作流程的完整性，优先选择能够缩短配製时间的产品（例如，可复溶的冻干製剂和预填充式注射器），从而减轻药房的负担并最大限度地降低无菌风险。

一项基于实证的混合调查方法，结合了临床医生访谈、供应链图谱分析和情境检验，得出了可操作且可复製的研究结果。

本分析所依据的研究结合了定性研究、系统的二手文献综述以及基于情景的供应链映射，以确保结论的稳健性和实用性。主要研究方法包括对感染疾病专家、医院药剂师、采购负责人和专科诊所主任进行结构化访谈，以收集有关临床偏好、竞标趋势和管理挑战的第一手观点。此外，与物流负责人和契约製造製造商的讨论也为生产限制和分销方面的考虑提供了参考。

简明综合分析强调，需要将临床优先事项与采购的韧性和运作严谨性相结合，以维持Echinocandins疗法的可及性。

综合分析结果支持一个核心结论：要提供持续、高品质的Echinocandins疗法，需要将临床优先事项与稳健的采购系统和灵活的供应链结合。虽然临床疗效仍然是不可动摇的基础，但製剂选择、分销策略和采购机制对疗效能否转化为及时的患者照护有显着影响。诸如配药工作量、低温运输要求和竞标主导的采购行为等现实挑战，需要将临床医生、药房营运和商业伙伴连接起来的综合解决方案。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章EchinocandinsB市场依产品类型划分

  • 原料药（API）
    • 粗製棘EchinocandinsB
    • 纯化棘EchinocandinsB
  • 衍生物的中间体
    • 卡福芬净中间体
    • Micafungin中间体
    • 阿尼芬净中间体
  • 最终配方
    • 注射剂
    • 口服製剂
  • 标准材料
  • 客製合成

第九章EchinocandinsB市场，依给药途径划分

  • 静脉注射
    • 持续输注
    • 间歇输注

第十章 棘EchinocandinsB市场（以剂型划分）

  • 冻干粉
    • 手动重新配置
    • 准备重新配置
  • 预填充式注射器

第十一章 棘EchinocandinsB市场依剂量方案

  • 每天一次
    • 高剂量
    • 标准剂量
  • 一天两次
    • 高剂量
    • 标准剂量

第十二章EchinocandinsB市场依包装分类

  • 多剂量包装
  • 单剂量包装

第十三章EchinocandinsB市场依通路划分

  • 医院药房
    • 直接竞标
    • 第三方竞标
  • 网路药房
  • 零售药房

第十四章 棘EchinocandinsB市场：依应用

  • 治疗研发
    • 抗真菌药物研发
    • 联合治疗研发
  • 商业生产
    • 原料药生产
    • 製药生产
  • 研究与开发
    • 作用机转研究
    • 电阻谱分析
    • 药物动力学研究
    • 毒性测试
  • 品管/分析
    • 参考标准物质
    • 检测标准化
    • 稳定性测试
  • 诊断用途
    • 霉菌药物敏感性试验
    • 生物标记检测方法开发

第十五章EchinocandinsB市场：依最终用户划分

  • 製药和生物技术公司
    • 品牌製药商
    • 学名药生产商
    • 契约製造组织
  • CRO（受託研究机构）
  • 学术和研究机构
  • 诊断实验室
  • 政府和非营利研究机构

第十六章EchinocandinsB市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章EchinocandinsB市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 各国棘EchinocandinsB市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

19. 美国EchinocandinsB市场

第二十章 中国的EchinocandinsB市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wockhardt Limited
  • Zydus Lifesciences Limited
Product Code: MRR-867BED9A9E72

The Echinocandin B Market was valued at USD 267.82 million in 2025 and is projected to grow to USD 305.95 million in 2026, with a CAGR of 12.54%, reaching USD 612.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 267.82 million
Estimated Year [2026] USD 305.95 million
Forecast Year [2032] USD 612.34 million
CAGR (%) 12.54%

A concise orientation to echinocandin therapy highlighting clinical importance, logistical challenges, and the strategic imperatives for continuity of care

Echinocandins have emerged as a cornerstone in the therapy of serious invasive fungal infections, offering a favorable therapeutic index and targeted activity that complements existing antifungal classes. These agents are integral to contemporary clinical protocols for invasive candidiasis and serve as an important option for select cases of esophageal candidiasis and invasive aspergillosis where treatment complexity demands reliable intravenous therapy. Over the past decade, clinical practice has emphasized stewardship, appropriate use, and rapid diagnostics to optimize outcomes while limiting resistance pressure.

Beyond clinical efficacy, the echinocandin landscape is shaped by manufacturing complexity, parenteral formulation requirements, and regulatory scrutiny surrounding biologic-like drug substances and their generics. Intravenous delivery, cold-chain handling, and reconstitution logistics create operational dependencies across hospitals, ambulatory centers, and specialty clinics. These realities influence procurement practices, tender design, and pharmacy workflow. Consequently, stakeholders must balance clinical imperatives with supply chain resiliency and cost-efficiency.

This introduction frames the subsequent analysis by underscoring the dual imperatives of clinical excellence and operational reliability. The report focuses on actionable insights for clinicians, supply chain managers, and commercial leaders who must navigate evolving therapeutic guidelines, product formulation choices, and distribution complexities to maintain uninterrupted access to echinocandin therapies.

How formulation innovation, tender dynamics, and evolving care pathways are collectively reshaping the production, procurement, and administration of echinocandin therapies

The echinocandin arena is undergoing transformative shifts driven by advances in formulation science, changes in procurement mechanisms, and evolving clinical guidance that together are reshaping how these therapies are produced, purchased, and administered. Recent formulation innovations, including ready-to-reconstitute lyophilized formats and prefilled syringe options, are reducing preparation time and minimizing dosing errors, and they are prompting hospitals and specialty clinics to reassess their inpatient and outpatient infusion practices. As a result, pharmacy teams are increasingly prioritizing products that streamline nursing workflows and reduce room-occupancy times.

Simultaneously, the rise of branded-to-generic transitions across anidulafungin, caspofungin, and micafungin is intensifying competition, which incentivizes manufacturers to differentiate through supply reliability, packaging innovations, and tender responsiveness. Distribution channels are also evolving: hospital pharmacies now balance direct tendering with third-party procurement arrangements, while online and retail pharmacies play expanding roles in outpatient continuity of care. These shifts are occurring in the context of heightened attention to antimicrobial stewardship and rapid diagnostic capabilities that support earlier targeted therapy.

Taken together, these developments are creating new opportunity spaces for strategic partnerships, contract manufacturing, and product modularity that align clinical needs with procurement realities. For organizations that proactively adapt to these transformations, there is potential to enhance treatment consistency and reduce downstream care disruptions.

An integrated assessment of how trade policy adjustments in 2025 have amplified supply chain risks, procurement behaviors, and access priorities across the echinocandin delivery ecosystem

The implementation of United States tariffs in 2025 introduced a pronounced set of cost and logistical pressures that reverberate through the echinocandin supply chain and clinical delivery pathways. At the upstream level, manufacturers faced elevated input costs for active pharmaceutical ingredients and specialized supplies, which in turn pressured production planning and led several contract manufacturers to reassess geographic footprints and supplier diversification strategies. These shifts had immediate implications for lead times and inventory buffers, prompting procurement teams in hospitals and ambulatory centers to place greater emphasis on multi-source qualification and safety stock protocols.

Downstream, hospital pharmacies and tendering bodies encountered increased volatility in unit acquisition costs. Procurement officers responded by intensifying negotiations, favoring tender structures that emphasize supply guarantees and penalties for nonperformance. In parallel, some institutions accelerated efforts to evaluate generic alternatives and ready-to-use formats that could reduce preparation labor and waste, thereby partially offsetting procurement cost pressures. Specialty clinics and outpatient infusion providers also recalibrated contracts with distributors to secure consistent product flow amid fluctuating shipping and customs expenses.

Clinically, access considerations gained prominence as formulary committees balanced cost containment with the imperative to maintain uninterrupted therapy for vulnerable patients. The tariff-driven environment further underscored the importance of strategic stock rotation, cross-facility sharing arrangements, and collaborations with regional suppliers to preserve treatment continuity. Ultimately, the cumulative impact of tariff policy has been to heighten the strategic value of resilient supply chains, contractual agility, and close collaboration between clinical and procurement leadership.

Multidimensional segmentation analysis revealing how product attributes, clinical applications, and distribution choices determine procurement, administration, and clinical outcomes

A granular appraisal of segmentation reveals actionable differentiation across product types, applications, end-user settings, distribution channels, administration routes, formulations, dosage regimens, and packaging formats that collectively influence procurement and clinical decision-making. Within product type, Anidulafungin, Caspofungin, and Micafungin each present distinct clinical positioning and operational profiles, and each is available in branded and generic forms, which affects contracting strategies and formulary placement. Clinicians consider these therapeutic distinctions alongside application contexts that include esophageal candidiasis, invasive aspergillosis, and invasive candidiasis, where disease severity and patient comorbidity profiles guide selection of specific agents and dosing approaches.

End-user segmentation spans ambulatory care centers, hospitals, and specialty clinics, and each setting imposes different priorities: hospitals typically emphasize availability and tender compliance, ambulatory centers prize ease of administration and outpatient continuity, while specialty clinics focus on infusion safety and reimbursement alignment. Distribution channels encompass hospital pharmacy, online pharmacy, and retail pharmacy pathways, with hospital pharmacy procurement further divided between direct tender and third-party tender arrangements, shaping lead times and contractual obligations.

Route of administration is predominantly intravenous and differentiates between continuous infusion and intermittent infusion practices, which in turn affect nursing workload and device selection. Formulation choices, such as lyophilized powder versus prefilled syringe formats, and the further distinction of lyophilized options between manual reconstitution and ready-to-reconstitute systems, directly impact bedside preparation time and aseptic manipulation risk. Dosage regimen segmentation into once daily and twice daily schedules, each with high-dose and standard-dose variants, influences dosing accuracy, pharmacoeconomic assessments, and adherence in outpatient settings. Finally, packaging preferences for multi-dose versus single-dose formats inform waste management, inventory control, and infection prevention measures. By synthesizing these segmentation layers, stakeholders can craft procurement and clinical strategies that align product attributes with care delivery realities.

A regional perspective on how procurement systems, manufacturing footprints, and clinical practice patterns uniquely influence echinocandin availability and care continuity

Regional dynamics materially shape the availability, adoption patterns, and operational approaches to echinocandin therapies, creating differentiated priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, hospital-centric care models and centralized procurement frameworks often drive large-scale tendering and a focus on supply reliability, while regulatory alignment and stewardship programs influence prescribing patterns and formulary decisions. These characteristics lead institutions to prioritize robust supplier relationships and contingency planning to mitigate disruptions.

Across Europe, the Middle East & Africa, heterogeneous reimbursement systems and tendering processes produce varied adoption timelines and contracting approaches. In some jurisdictions, centralized tenders and national procurement mechanisms create price sensitivity and emphasize compliance with quality certifications, whereas other regions prioritize local supplier engagement and rapid response capabilities to preserve access in geographically dispersed care networks.

The Asia-Pacific region combines strong manufacturing capacity with rapid uptake of generics and novel distribution models. Production hubs within the region contribute to a complex interplay between export dynamics and domestic supply priorities, while diverse healthcare delivery settings-from tertiary hospitals to community infusion centers-drive differentiated demand for ready-to-use formulations and single-dose packaging. Across all regions, regional regulatory frameworks, logistics infrastructure, and clinical practice patterns determine how product attributes and procurement strategies translate into real-world access and patient care continuity.

Insights into how manufacturers, contract producers, and distributors are competing through supply assurance, formulation differentiation, and value-added service models

Competitive dynamics among manufacturers, contract producers, and distributors are central to shaping supply reliability, product differentiation, and commercial strategy. Innovator firms and established suppliers have focused investments on formulation improvements, supply chain transparency, and tender responsiveness to maintain long-term relationships with hospital chains and procurement consortia. At the same time, generic entrants and contract manufacturing organizations are expanding capacity and pursuing certifications that facilitate inclusion in multiple tender frameworks, thereby increasing sourcing options for large buyers.

Strategic behaviors include pursuing licensing agreements, forming regional distribution partnerships, and offering value-added services such as inventory management, on-site pharmacy training, and product readiness support. Companies that align commercial models with hospital pharmacy workflows by providing ready-to-reconstitute products, prefilled syringes, or simplified dosing guides often gain preference in formularies where preparation time and infection control are high priorities. Additionally, some manufacturers are prioritizing investments in cold-chain logistics and serialized tracking to meet compliance expectations and to demonstrate superior supply assurance.

Given procurement pressures and regulatory expectations, firms are also deploying differentiated tender strategies that combine competitive pricing with contractual guarantees on supply continuity. Those that proactively engage clinical stakeholders to generate real-world evidence and to support stewardship initiatives strengthen their positioning with health systems focused on both outcomes and operational efficiency.

Practical, high-impact recommendations for strengthening procurement agility, clinical alignment, and supply chain resilience in echinocandin therapy delivery

Industry leaders should adopt a multi-pronged strategy that addresses clinical continuity, procurement agility, and supply chain resilience to navigate the evolving echinocandin landscape. First, prioritize supplier diversification and dual-sourcing arrangements to reduce exposure to single points of failure, while negotiating contractual safety nets that include volume flexibility and penalties for nonperformance. Second, invest in formulation and workflow alignment by preferring products that reduce preparation time-such as ready-to-reconstitute lyophilized formats or prefilled syringes-to lower nursing burden and minimize aseptic risk.

Third, strengthen collaboration between clinical, pharmacy, and procurement teams to expedite decision-making and to align tender specifications with therapeutic priorities and administration realities. Fourth, pursue value-based contracting models and outcome-linked agreements where feasible, using real-world evidence to demonstrate clinical and operational benefits that justify premium pricing or preferential placement. Fifth, enhance cold-chain and inventory visibility through serialization and integrated logistics platforms to reduce waste and to improve traceability during shipment and storage.

Finally, develop contingency playbooks that include regional redistribution mechanisms, cross-facility sharing protocols, and engagement plans with regulatory authorities to facilitate expedited approvals or importation during supply stress. These combined actions will improve resilience and create competitive advantage for organizations that must deliver uninterrupted echinocandin therapy across acute and ambulatory care settings.

An evidence-based mixed-methods research approach combining clinician interviews, supply chain mapping, and scenario validation to produce actionable and reproducible findings

The research underpinning this analysis integrated primary qualitative inquiry, systematic secondary review, and scenario-based supply chain mapping to ensure conclusions are robust and actionable. Primary methods included structured interviews with infectious disease specialists, hospital pharmacists, procurement officers, and specialty clinic directors to capture frontline perspectives on clinical preferences, tender dynamics, and administration challenges. These insights were complemented by consultations with logisticians and contract manufacturers to understand production constraints and distribution sensitivities.

Secondary analysis comprised a targeted review of regulatory guidance, clinical practice updates, and publicly available technical documentation on formulation and administration practices. Supply chain mapping involved tracing key nodes from active pharmaceutical ingredient sourcing through final product distribution, identifying critical bottlenecks, and stress-testing these nodes under tariff- and policy-induced disruption scenarios. Data triangulation and validation workshops with subject matter experts refined assumptions and ensured alignment between clinical realities and procurement imperatives.

Finally, the methodology emphasized transparency and reproducibility: data sources and interview protocols were documented, stakeholder feedback was incorporated iteratively, and scenario outputs were reviewed with clinical and supply chain leaders to ensure practical relevance. This mixed-method approach supports the strategic recommendations and operational actions presented throughout the report.

A concise synthesis emphasizing the imperative to align clinical priorities with procurement resilience and operational rigor to sustain echinocandin therapy access

The aggregated analysis underscores a central conclusion: delivering consistent, high-quality echinocandin therapy requires aligning clinical priorities with resilient procurement and adaptable supply chains. Clinical efficacy remains the non-negotiable foundation, but formulation choices, distribution strategies, and procurement mechanisms materially affect whether that efficacy translates into timely patient care. Real-world challenges such as preparation complexity, cold-chain requirements, and tender-driven procurement behaviors necessitate integrated solutions that bridge clinicians, pharmacy operations, and commercial partners.

Moreover, policy and trade developments have amplified the need for proactive risk management, driving organizations to diversify suppliers, enhance inventory visibility, and design tenders that reward supply reliability alongside cost-efficiency. Regional and segment-specific nuances-from hospital-centric demand in some geographies to manufacturing-driven dynamics in others-require tailored approaches rather than one-size-fits-all solutions. By operationalizing recommendations around supplier diversification, formulation alignment, and collaborative contracting, stakeholders can reduce the probability of care disruptions and improve both operational and clinical outcomes.

In sum, strategic foresight, operational rigor, and clinical engagement are the pillars that will determine which organizations successfully navigate the current landscape and maintain uninterrupted access to essential echinocandin therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Echinocandin B Market, by Product Type

  • 8.1. Active Pharmaceutical Ingredient (API)
    • 8.1.1. Crude Echinocandin B
    • 8.1.2. Purified Echinocandin B
  • 8.2. Intermediate For Derivatives
    • 8.2.1. Caspofungin Intermediate
    • 8.2.2. Micafungin Intermediate
    • 8.2.3. Anidulafungin Intermediate
  • 8.3. Finished Dosage Form
    • 8.3.1. Injectable Formulations
    • 8.3.2. Oral Formulations
  • 8.4. Reference Standard
  • 8.5. Custom Synthesis

9. Echinocandin B Market, by Route Of Administration

  • 9.1. Intravenous
    • 9.1.1. Continuous Infusion
    • 9.1.2. Intermittent Infusion

10. Echinocandin B Market, by Formulation

  • 10.1. Lyophilized Powder
    • 10.1.1. Manual Reconstitution
    • 10.1.2. Ready To Reconstitute
  • 10.2. Prefilled Syringe

11. Echinocandin B Market, by Dosage Regimen

  • 11.1. Once Daily
    • 11.1.1. High Dose
    • 11.1.2. Standard Dose
  • 11.2. Twice Daily
    • 11.2.1. High Dose
    • 11.2.2. Standard Dose

12. Echinocandin B Market, by Packaging

  • 12.1. Multi Dose Packaging
  • 12.2. Single Dose Packaging

13. Echinocandin B Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
    • 13.1.1. Direct Tender
    • 13.1.2. Third Party Tender
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Echinocandin B Market, by Application

  • 14.1. Therapeutic Development
    • 14.1.1. Antifungal Drug Development
    • 14.1.2. Combination Therapy Development
  • 14.2. Commercial Production
    • 14.2.1. Bulk Drug Manufacturing
    • 14.2.2. Formulation Manufacturing
  • 14.3. Research & Development
    • 14.3.1. Mechanistic Studies
    • 14.3.2. Resistance Profiling
    • 14.3.3. Pharmacokinetic Studies
    • 14.3.4. Toxicology Studies
  • 14.4. Quality Control & Analytics
    • 14.4.1. Reference Standards
    • 14.4.2. Assay Calibration
    • 14.4.3. Stability Testing
  • 14.5. Diagnostic Use
    • 14.5.1. Fungal Susceptibility Testing
    • 14.5.2. Biomarker Assay Development

15. Echinocandin B Market, by End User

  • 15.1. Pharmaceutical & Biotechnology Companies
    • 15.1.1. Branded Drug Manufacturers
    • 15.1.2. Generic Drug Manufacturers
    • 15.1.3. Contract Manufacturing Organizations
  • 15.2. Contract Research Organizations
  • 15.3. Academic & Research Institutes
  • 15.4. Diagnostic Laboratories
  • 15.5. Government & Nonprofit Research Bodies

16. Echinocandin B Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Echinocandin B Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Echinocandin B Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Echinocandin B Market

20. China Echinocandin B Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Amneal Pharmaceuticals, Inc.
  • 21.6. Apotex Inc.
  • 21.7. Astellas Pharma Inc.
  • 21.8. Cipla Limited
  • 21.9. Dr. Reddy's Laboratories Ltd.
  • 21.10. F. Hoffmann-La Roche Ltd.
  • 21.11. Fresenius SE & Co. KGaA
  • 21.12. Gilead Sciences, Inc.
  • 21.13. GlaxoSmithKline plc
  • 21.14. Glenmark Pharmaceuticals Ltd.
  • 21.15. Hikma Pharmaceuticals PLC
  • 21.16. Merck & Co., Inc.
  • 21.17. Novartis AG
  • 21.18. Pfizer Inc.
  • 21.19. Sanofi
  • 21.20. Sun Pharmaceutical Industries Ltd.
  • 21.21. Teva Pharmaceutical Industries Ltd.
  • 21.22. Viatris Inc.
  • 21.23. Wockhardt Limited
  • 21.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ECHINOCANDIN B MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ECHINOCANDIN B MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ECHINOCANDIN B MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ECHINOCANDIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLIO